Biohaven Pharmaceutical Holding Company Ltd. Share-based Payment Arrangement, Expense
Biohaven Pharmaceutical Holding Company Ltd. reported Share-based Payment Arrangement, Expense of $16.88 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2020-05-07
- Biohaven Pharmaceutical Holding Company Ltd. share-based payment arrangement, expense for the quarter ending 2020-03-31 was $16.88M, a 130.27% increase year-over-year.
- Biohaven Pharmaceutical Holding Company Ltd. share-based payment arrangement, expense for the quarter ending 2019-03-31 was $7.33M.
- Biohaven Pharmaceutical Holding Company Ltd. share-based payment arrangement, expense for the quarter ending 2017-12-31 was $2.43M, a 0.08% decline year-over-year.
- Biohaven Pharmaceutical Holding Company Ltd. share-based payment arrangement, expense for the quarter ending 2017-09-30 was $6.26M, a 740.86% increase year-over-year.
- Biohaven Pharmaceutical Holding Company Ltd. share-based payment arrangement, expense for fiscal 2019 was $54.97M, a 224.80% increase from fiscal 2018.
- Biohaven Pharmaceutical Holding Company Ltd. share-based payment arrangement, expense for fiscal 2018 was $16.93M, a 27.84% increase from fiscal 2017.
- Biohaven Pharmaceutical Holding Company Ltd. share-based payment arrangement, expense for fiscal 2017 was $13.24M, a 187.62% increase from fiscal 2016.
- Biohaven Pharmaceutical Holding Company Ltd. share-based payment arrangement, expense for fiscal 2016 was $4.60M, a 62.25% increase from fiscal 2015.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2020-03-31 | $16.88M 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $54.97M 10-K · filed 2020-02-26 | |||
| 2019-03-31 | $7.33M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $16.93M 10-K · filed 2020-02-26 | |||
| 2017-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $8.69M derived: sum of 2 quarters · filed 2020-02-26 | $11.35M derived: sum of 3 quarters · filed 2020-02-26 | $13.24M 10-K · filed 2020-02-26 |
| 2017-09-30 | $6.26M 10-Q · filed 2017-11-14 | $8.92M derived: sum of 2 quarters · filed 2017-11-14 | $10.80M 10-Q · filed 2017-11-14 | $13.24M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $2.66M 10-Q · filed 2017-08-14 | $4.55M 10-Q · filed 2017-08-14 | $6.99M derived: sum of 3 quarters · filed 2019-02-28 | $7.73M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $1.89M 10-Q · filed 2017-06-16 | $4.32M derived: sum of 2 quarters · filed 2019-02-28 | $5.07M derived: sum of 3 quarters · filed 2019-02-28 | $5.80M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $3.18M derived: sum of 2 quarters · filed 2019-02-28 | $3.92M derived: sum of 3 quarters · filed 2019-02-28 | $4.60M 10-K · filed 2019-02-28 |
| 2016-09-30 | $744.00K 10-Q · filed 2017-11-14 | $1.48M derived: sum of 2 quarters · filed 2017-11-14 | $2.17M 10-Q · filed 2017-11-14 | |
| 2016-06-30 | $736.00K 10-Q · filed 2017-08-14 | $1.42M 10-Q · filed 2017-08-14 | ||
| 2016-03-31 | $687.00K 10-Q · filed 2017-06-16 | |||
| 2015-12-31 | $2.84M 10-K · filed 2018-03-06 |